Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

Add To Watchlist

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > That was too easy, guess you missed it

View:

Post by Red~One on Jan 19, 2022 9:32am

That was too easy, guess you missed it

"“Additionally, we are negotiating to obtain exclusive worldwide rights to develop and commercialize R-107 for the treatment of skin ulcers and wound healing, including the treatment of severe burns."

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

V.CLAS | January 4, 2022

182

Comment

Comment by PTBailey on Jan 19, 2022 10:35am

That was too easy, guess you missed it. January 4 we were 'negotiating' for rights however, Jan.17 we announced that the negotiations are over and we "will enter into a new license agreement" Is this not a material development? "Claritas will enter into a new license agreement with Salzman Group for the development and commercialization of R-107 for the ...more

Comment

Claritas Pharmaceuticals Inc